Deconstructing IgG4-RD: The Imperative for Genetic, Immunologic, and Metabolic Endotyping in the Pursuit of Precision Therapy

Mitochondrial Dysfunction in Viral Neuropathogenesis: Unaddressed Challenges from Mechanism to Therapeutic Translation.

Methodological Limitations and Unanswered Questions in the Real-World Assessment of Mepolizumab for Severe Asthma with Comorbid CRSwNP

The Tonsillar Virome in Rheumatoid Arthritis: A Critical Appraisal of Its Diagnostic Promise and Unresolved Etiological LinksAuthorsLiSheng Qi,QinWen Gu,DuJiang Yang,Bo Chen,DongDong Li*

This letter provides a critical analysis of the recent study by Wang et al. (Adv. Mater. 2025, agt2.70101) on the use of tungsten oxide (WOx) nanosheets for acute kidney injury (AKI) therapy. While acknowledging the novelty of the approach, we identify several key limitations that challenge the authors’ conclusions. Specifically, we argue that the evidence for geometry-enhanced renal targeting is inconclusive, potentially conflating specific targeting with non-specific accumulation in inflamed tissues. The proposed antioxidant mechanism, though supported by in vitro data, lacks depth in vivo and fails to elucidate the underlying molecular pathways. Most critically, the long-term biocompatibility and potential toxicity of tungsten-based nanomaterials remain largely unaddressed, a significant hurdle for clinical translation. Furthermore, the reliance on a single, acute AKI model limits the generalizability of the findings. We urge for more rigorous validation, including comprehensive pharmacokinetic studies, systems-level mechanistic inquiry, detailed long-term toxicological assessments, and evaluation in diverse disease models. Addressing these concerns is paramount to accurately assessing the therapeutic potential and translational viability of WOx nanosheets.

This Letter provides a critical analysis and prospective outlook on the field of organic charge-transfer (CT) photothermal cocrystals for biomedical applications, as recently reviewed by Khan et al. While acknowledging the significant promise of these materials as highly tunable photothermal agents, we identify several pivotal challenges that must be addressed to pave their translational path. Specifically, we emphasize the urgent need for comprehensive investigations into the in vivo stability, long-term biocompatibility, and clearance pathways of these molecular solids, which present unique complexities compared to single-component systems. Furthermore, we argue that the pursuit of high photothermal conversion efficiency must be coupled with strategies for targeted activation and spatial control of thermal energy to ensure treatment specificity. Finally, we highlight the immense potential of integrating CT cocrystals into multimodal therapeutic platforms, combining photothermal therapy with chemotherapy, radiotherapy, or imaging modalities. Addressing these critical aspects will be paramount in transforming this exciting class of materials from a laboratory innovation into a viable clinical therapy.

In their seminal study, Sun et al. delineate a novel pathway wherein SIRT2-mediated deacetylation of ANXA2 promotes protective autophagy, thereby conferring resistance to donafenib in hepatocellular carcinoma (HCC). This work provides a compelling mechanistic explanation for a significant clinical challenge. Our letter offers a prospective critique of these findings. We posit that while the SIRT2-ANXA2-ATG4B axis represents a bona fide therapeutic target, its clinical translation necessitates a more nuanced appraisal. Key considerations include the context-dependent duality of SIRT2 as both an oncogene and tumor suppressor, which may dictate heterogeneous responses across HCC etiologies. Furthermore, the biochemical mechanism linking ANXA2 deacetylation to enhanced autophagic flux warrants deeper interrogation, particularly regarding the functional impact on ATG4B protease activity. Finally, we emphasize the paramount importance of evaluating the therapeutic index of combining donafenib with SIRT2 or autophagy inhibition, as potential on-target toxicities in normal tissues could limit clinical applicability. Future efforts should focus on defining predictive biomarkers for patient stratification. In conclusion, the study by Sun et al. opens crucial new avenues; however, overcoming the outlined challenges is essential for harnessing this knowledge into effective therapeutic strategies.

This letter discusses the groundbreaking work by Lou et al. (2025) on biomimetic extracellular vesicle spherical nucleic acids (EV-SNAs) for pulmonary fibrosis therapy. By synergistically combining the innate biological properties of extracellular vesicles with the programmable functionality of spherical nucleic acids, this platform demonstrates exceptional lung-targeting capability and therapeutic efficacy through dual ROS scavenging and anti-inflammatory mechanisms. We analyze the transformative potential of this approach while addressing the critical challenges of scalability, long-term safety, and clinical translation that must be overcome to realize its full therapeutic promise.

The recent development of a novel supramolecular probe for monitoring lysosomal ferritinophagy, as reported by Zhou et al., represents a paradigm-shifting advancement in the quest for early Parkinson’s disease (PD) diagnostics. This letter provides a critical analysis and forward-looking perspective on this technology. We discuss how targeting ferritinophagy—a pivotal process in iron dyshomeostasis and ferroptosis—offers a functionally relevant biomarker for detecting PD pathogenesis long before overt neurodegeneration occurs. The supramolecular design strategy is lauded for its potential for high specificity and signal amplification within the challenging lysosomal environment. Beyond its immediate diagnostic implications, this probe is positioned as an indispensable research tool for elucidating the precise role of iron-mediated cell death in neurodegeneration and for accelerating the screening of novel therapeutic agents that modulate this pathway. We conclude by addressing the translational pathway and the remaining challenges that must be overcome to move this promising technology from bench to bedside, ultimately paving the way for preventative neuroprotective strategies.

The recent paradigm shift in nanomedicine—from passive drug delivery to active engagement with biological responses—holds great promise for advancing cancer therapy. However, the clinical translation of this approach faces significant challenges. In this letter, we highlight three critical areas requiring deeper investigation: (1) the dynamic interplay and potential antagonism between nanomaterial-induced biological pathways, such as reactive oxygen species (ROS) generation and protective autophagy; (2) the dual role of inflammation, which can either promote antitumor immunity or drive immunosuppression; and (3) the translational gap between preclinical models and human patients, emphasizing the impact of biological heterogeneity on therapeutic outcomes. We propose integrating systems biology, feedback-controlled mechanisms, and biomarker-driven clinical trials to overcome these challenges and realize the full potential of nanomaterial-enabled cancer therapies.